EGT-101 is under clinical development by Esteve Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect EGT-101’s likelihood of approval (LoA) and phase transition for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) took place on 07 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their EGT-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

EGT-101 overview

EGT-101 is under development for the treatment of Sanfilippo syndrome type A. It is administered through intracerebroventricular route. The therapeutic candidate utilizes adeno-associated virus vector serotype 9 (AAV9) to deliver the human sulfoglucosamine sulfohydrolase gene  (AAV9-sulfamidase). It is developed based on NAV technology.

Esteve Pharmaceuticals overview

Esteve Pharmaceuticals (Esteve) researches, develops, and markets prescription and generic pharmaceuticals. The company’s product portfolio encompasses innovative prescription drugs, over the counter (OTC) pharmaceuticals and generic drugs. It offers drugs in central nervous system, infection, respiratory, cardiovascular, cancer, primary care, and other therapeutic areas. Esteve also provides customized contract manufacturing services of active pharmaceutical ingredients (APIs) and advanced intermediates for the global pharmaceutical industry. The company markets its products to pharmaceutical companies, healthcare facilities and other customers through licensing agreements and distributors. It operates subsidiaries and production centers in Europe, the Americas, Africa, Oceania, and Asia. Esteve is headquartered in Barcelona, Spain.

Quick View EGT-101 LOA Data

Report Segments
  • Innovator
Drug Name
  • EGT-101
Administration Pathway
  • Parenteral
Therapeutic Areas
  • Genetic Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.